Shares of Arbutus Biopharma (NASDAQ:ABUS) have been assigned a consensus recommendation of “Hold” from the nine research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $13.80.
A number of research firms have commented on ABUS. ValuEngine upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Thursday. BidaskClub upgraded Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, March 10th. Chardan Capital restated a “buy” rating on shares of Arbutus Biopharma in a research report on Tuesday, January 16th. Zacks Investment Research downgraded Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, January 18th. Finally, B. Riley began coverage on Arbutus Biopharma in a research report on Friday, January 5th. They issued a “buy” rating and a $10.00 target price on the stock.
Arbutus Biopharma (NASDAQ ABUS) remained flat at $$5.25 during trading hours on Friday. 287,902 shares of the company’s stock were exchanged, compared to its average volume of 119,288. Arbutus Biopharma has a fifty-two week low of $2.95 and a fifty-two week high of $8.25. The company has a quick ratio of 11.03, a current ratio of 11.03 and a debt-to-equity ratio of 0.08. The company has a market cap of $289.27, a PE ratio of -3.39 and a beta of 1.02.
Several hedge funds have recently bought and sold shares of ABUS. Spark Investment Management LLC raised its holdings in shares of Arbutus Biopharma by 98.3% in the 4th quarter. Spark Investment Management LLC now owns 23,000 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 11,400 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Arbutus Biopharma in the 4th quarter valued at $146,000. Two Sigma Investments LP purchased a new stake in shares of Arbutus Biopharma in the 4th quarter valued at $215,000. Goldman Sachs Group Inc. purchased a new stake in shares of Arbutus Biopharma in the 4th quarter valued at $275,000. Finally, Vanguard Group Inc. raised its holdings in shares of Arbutus Biopharma by 2.7% in the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 2,035 shares during the period. Hedge funds and other institutional investors own 62.14% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Arbutus Biopharma (ABUS) Receives Average Recommendation of “Hold” from Analysts” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3276141/arbutus-biopharma-abus-receives-average-recommendation-of-hold-from-analysts.html.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.